top of page
Search

Cell and Gene Therapy Updates

May 1st & 2nd Week, 2025



⭐ Deals & Collaborations


🤝 NKure Therapeutics and CRISPR Therapeutics partnered to co-develop CRISPR’s CTX112 (an allogeneic, anti-CD19 CAR-T) for the treatment of R/R B-cell malignancies in India. NKure plans to seek the CDSCO approval by Jun’25 to begin Ph2 trials in India (Ref 1) 


❓ What is the competitive landscape of CAR-Ts in India? 



🤝 Chong Kun Dang Pharm. acquired a 7.3% stake in AbClon, and received priority rights to commercialize nespecabtagene autoleucel (AT101; an autologous, anti-CD19 CAR-T) which is in Ph2/NCT05338931 clinical trial for the treatment of R/R B-cell NHL. Both the companies plan to jointly develop additional CAR-T therapies (Ref 2) 


❓ What are the key outcomes reported till date from the Ph2 trial of nespe-cel? 



⭐ Clinical Data Readouts


🔬Updated results from the Ph1/NCT06325748 trial of Senti Biosciences’ SENTI-202 (an allogeneic, logic-gated selective CD33/FLT3 CAR-NK) were presented at AACR’25, showing an ORR of 71.4% in 7 evaluable pts with R/R AML, with no DLTs observed (Ref 3) 


❓ What is the significance of the logic-gated design? 



🔬 First-time results from an early exploratory study of CARsgen Therapeutics’ CT0596 (an allogeneic, anti-BCMA CAR-T using THANK-u Plus platform) achieved 60.0% sCR/CR in 5 efficacy evaluable pts with no DLTs, Gr ≥3 CRS, ICANS among the 8 pts recruited with ≥4L R/R MM (Ref 4) 


❓ How is the THANK-u Plus platform leveraged in its development? 



⭐ Setbacks 


🛑 Vor Bio announced its exploration of strategic alternatives, citing an assessment of clinical program data and ongoing fundraising challenges as key factors in the decision. The company clarified that the wind-down is not driven by safety concerns related to any of its assets. (Ref 5) 


❓ Which Vor Biopharma's CGT assets were discontinued because of this decision?



To know answers to these questions and for additional insights, write to us at support@oncofocus.com.



 🌐 References



Comments

Commenting on this post isn't available anymore. Contact the site owner for more info.
bottom of page